Biovie is trading at $1.29, with a -5.84% change and no clear catalyst identified. - No company-specific announcement dated October 20 was identified. BioVie’s October 19 update presented Phase 2 Long COVID results. - Results showed benefits in certain subgroups, but the overall trial population did not achieve statistical significance on any endpoint. - Biotech rose during the regular session, so sector context does not explain the decline; no trading-volume details were found.